atorvastatin + acetylcholinesterase inhibitor

**atorvastatin + acetylcholinesterase inhibitor** is a hypothetical or investigational combination therapy consisting of two pharmacological agents: - **atorvastatin**, a statin used primarily for lowering cholesterol and cardiovascular risk, and - **an acetylcholinesterase inhibitor**, a class of drugs commonly used to increase central cholinergic activity in conditions like Alzheimer's disease. Atorvastatin acts by competitively inhibiting HMG-CoA reductase, leading to decreased cholesterol synthesis and upregulation of LDL receptors. Acetylcholinesterase inhibitors (examples: donepezil, rivastigmine, galantamine) block the breakdown of acetylcholine, thereby enhancing cholinergic neurotransmission in the brain. Limited clinical studies have explored using atorvastatin in combination with an acetylcholinesterase inhibitor (e.g., donepezil) for Alzheimer's disease, hypothesizing additive or synergistic effects on cognition or neuroprotection, but no branded or generic fixed-dose combination product appears marketed or widely established[5][9]. This combination represents a co-administration rather than a uniquely formulated fixed-combination drug.